Polaris Market Research values the semaglutide market at USD 32.22 billion in 2025 and projects USD 81.08 billion by 2034, at a CAGR of 10.8% from 2026 to 2034. The industry is characterized by high entry barriers, including rigorous regulatory standards, substantial R&D expenditure, the complexity of peptide drug development, and Novo Nordisk's robust intellectual property protections....